An Open-Label Study to Assess the Safety and Tolerability of Active Immunotherapy With Escalating Doses of OBI-833/OBI-821 (Globo H-CRM197/OBI-821) in Subjects With Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer

Trial Profile

An Open-Label Study to Assess the Safety and Tolerability of Active Immunotherapy With Escalating Doses of OBI-833/OBI-821 (Globo H-CRM197/OBI-821) in Subjects With Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs OBI 833 (Primary)
  • Indications Breast cancer; Colorectal cancer; Gastric cancer; Lung cancer
  • Focus Adverse reactions; First in man
  • Sponsors OBI Pharma
  • Most Recent Events

    • 29 Nov 2016 Planned number of patients changed from 26 to 58.
    • 09 Sep 2016 Planned End Date changed from 1 Nov 2017 to 1 Dec 2018.
    • 09 Sep 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top